Joint Annual Research Report 2004 - The Royal Marsden

More documents

Recommendations

Info

Financial Facts and Figures The principal sources of income and the expenditure of our joint institution are summarised in the Facts and Figures page (page 12). Full and detailed statements of the financial accounts of The Institute of Cancer Research (August 2003 to July 2004) and The Royal Marsden NHS Foundation Trust (April 2004 to March 2005, to be published in September 2005) are separately recorded in our respective Annual Reports and Accounts. In the financial year ending on 31 March 2005, the Trust met its key financial objectives and achieved a balanced budget. In the financial year ending on 31 July 2004, The Institute achieved a balanced budget on unrestricted funds after transfers. Its expenditure on research grew by 10.7% from the previous year, with increases in research expenditure across a number of research Sections. Overall, the combined annual turnover of our organisation was £203.1 million, with 89% of this total being devoted to research activities and patient care services. Government funding for our joint research activities contributes 42% of the total resources for research. Our success rate in competing for research funding from external sources continues to be outstanding, at 75% of the value of all applications for peerreviewed grants to medical charities and government funding agencies. The Institute is particularly indebted to its major funding partners – Cancer Research UK, Breakthrough Breast Cancer, Leukaemia Research, the Wellcome Trust, the Medical Research Council, Department of Health, and many other medical research sponsors. New commercial partners collaborating in drug development at The Institute and supporting clinical trials at the Royal Marsden include: AstraZeneca, Novartis, Vernalis Ltd, Astex Technology Ltd, Pfizer, Antisoma and BTG. Many organisations also contribute support by providing funds for studentships at The Institute and clinical fellowships at the hospital. The Royal Marsden and The Institute are grateful to all the numerous organisations and supporters who have made investments in our research activities. Fundraising The Royal Marsden publicly launched its £30 million appeal to finance a number of major projects to provide a range of new facilities and leading edge equipment which will enhance the hospital’s research capacity as well as provide improved treatments for patients. Generous gifts from an anonymous charitable foundation, the Oak Foundation, the Garfield Weston Foundation, John and Catherine Armitage, the PF Charitable Trust, the Wolfson Foundation, the Arbib Foundation, Martin Myers and a number of other trusts and private individuals, brought the sum pledged to £24 million by the end of the year. The loyal support of the hospital’s staff and patients, their families and friends and the general public contributed some £2 million to that total. Our thanks go to all the dedicated people who have done so much to bring the appeal’s final target in sight so speedily. The Institute continues to receive significant support from charitable trusts, companies and an increasing number of individuals. Our Everyman Male Cancer
REVIEW OF 2004 Campaign attracted unprecedented support during 2004 which included partnerships with Topman, The Football Association, The Professional Footballers’ Association and Gillette UK, among many others. We extend our most grateful thanks to all those who have contributed to our continuing success, including The Grand Charity of Freemasons, the Garfield Weston Foundation, ICAP plc and the many individuals, trusts and companies who have supported The Institute through donations or attendance at fundraising occasions. With over 90% of our total income going directly into research The Institute remains one of the most cost-effective cancer research organisations in the world. It is a great pleasure to present this, our joint Annual Research Report for 2004. We pay tribute to everyone who has contributed to our achievements this year, not least our outstanding scientists and clinicians whose excellence and dedication keep The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research at the forefront of world-class cancer research. Tessa Green Chairman Cally Palmer Chief Executive The Royal Marsden NHS Foundation Trust Lord Faringdon Chairman Professor Peter Rigby Chief Executive The Institute of Cancer Research 11
Page 1 and 2: ANNUAL RESEARCH REPORT 2004 The Roy
Page 3 and 4: CONTENTS Review of 2004 - from the
Page 5 and 6: Cancer genes Scientific Strategy: f
Page 7 and 8: REVIEW OF 2004 tumours. It is highl
Page 9: REVIEW OF 2004 While there have bee
Page 13 and 14: Academic Dean’s Report 2004 Our a
Page 15 and 16: ACADEMIC DEAN’S REPORT 2004 We ac
Page 17 and 18: Technology Transfer Report 2004 The
Page 19 and 20: TECHNOLOGY TRANSFER Figure 1. The V
Page 21 and 22: differentiated lactating lobules ar
Page 23 and 24: CANCER BIOLOGY SMAC ’em dead It i
Page 25 and 26: Extracellular environment Signal Re
Page 27 and 28: CANCER THERAPEUTICS/CANCER BIOLOGY
Page 29 and 30: Examples of current projects A vari
Page 31 and 32: CANCER THERAPEUTICS No. of patients
Page 33 and 34: CANCER THERAPEUTICS molecular diagn
Page 35 and 36: e very useful. Examples include tha
Page 37 and 38: CANCER THERAPEUTICS Integrating new
Page 39 and 40: The duration of adjuvant chemothera
Page 41 and 42: CANCER THERAPEUTICS Future directio
Page 43 and 44: Figure 1. Superficial spreading mel
Page 45 and 46: CANCER THERAPEUTICS Four randomised
Page 47 and 48: Lung cancer In collaboration with D
Page 49 and 50: IMAGING RESEARCH & CANCER DIAGNOSIS
Page 51 and 52: (a) (b) Figure 1. Whole mount betag
Page 53 and 54: CANCER BIOLOGY/RADIOTHERAPY metasta
Page 55 and 56: It is likely that the causes of eac
Page 57 and 58: HEALTH RESEARCH The Breakthrough Ge
Page 59 and 60: elative risk of developing breast c
Page 61 and 62:
HEALTH RESEARCH Accordingly, in our
Page 63 and 64:
In addition to browsing lists of re
Page 65 and 66:
MOLECULAR PATHOLOGY Section of Haem
Page 67 and 68:
ACADEMIC BOARD The Institute and th
Page 69 and 70:
SENIOR STAFF & COMMITTEES 2004 MEDI
show all

Joint Annual Research Report 2004 - The Royal Marsden

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?